Top Page
Tong Ren Tang Technologies Co
(1666)
Tong Ren Tang Technologies Co (1666) vs. iShares MSCI Hong Kong ETF (EWH)
Tong Ren Tang Technologies Co Business Overview & Revenue Model
Tong Ren Tang Technologies Co Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.95B | 7.26B | 6.77B | 5.99B | 5.40B | 4.61B |
| Gross Profit | 2.77B | 2.88B | 2.85B | 2.59B | 2.29B | 2.07B |
| EBITDA | 1.11B | 1.17B | 1.30B | 1.39B | 1.26B | 1.14B |
| Net Income | 431.71M | 521.79M | 590.19M | 582.89M | 507.25M | 467.55M |
Balance Sheet | ||||||
| Total Assets | 14.54B | 14.41B | 13.51B | 12.48B | 11.59B | 10.94B |
| Cash, Cash Equivalents and Short-Term Investments | 5.15B | 4.38B | 4.24B | 4.18B | 3.89B | 3.49B |
| Total Debt | 2.41B | 2.43B | 1.63B | 1.59B | 1.64B | 1.69B |
| Total Liabilities | 4.33B | 4.24B | 3.86B | 3.47B | 3.44B | 3.19B |
| Stockholders Equity | 7.30B | 7.21B | 6.89B | 6.48B | 5.98B | 5.73B |
Cash Flow | ||||||
| Free Cash Flow | 1.44B | -158.56M | 450.78M | 565.85M | 877.01M | -110.09M |
| Operating Cash Flow | 1.59B | 15.61M | 554.17M | 723.77M | 1.03B | 435.81M |
| Investing Cash Flow | -116.24M | 1.05B | -1.07B | 43.01M | -197.36M | -195.44M |
| Financing Cash Flow | -634.06M | 288.35M | -497.76M | -499.45M | -474.67M | -164.51M |
Tong Ren Tang Technologies Co Technical Analysis
Tong Ren Tang Technologies Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$6.66B | 7.47 | 10.85% | 5.76% | -20.64% | -25.39% | |
68 Neutral | $5.97B | 12.84 | 5.98% | 4.15% | 0.73% | -34.04% | |
66 Neutral | $7.32B | 14.20 | 13.22% | 3.94% | 24.13% | 4.29% | |
57 Neutral | HK$9.86B | 51.80 | 6.73% | ― | 23.37% | ― | |
54 Neutral | $11.63B | -40.67 | -1.26% | 3.35% | -9.58% | -128.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Tong Ren Tang Technologies Co Corporate Events
Tong Ren Tang Technologies Co. announced a delay in the dispatch of a circular related to the renewal of continuing connected transactions under the Distribution Framework Agreement and the Master Procurement Agreement. The delay, which pushes the dispatch date to on or before November 30, 2025, is due to the additional time needed to finalize the circular’s details and arrange its publication.
The most recent analyst rating on (HK:1666) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on Tong Ren Tang Technologies Co stock, see the HK:1666 Stock Forecast page.
Tong Ren Tang Technologies Co, a joint stock company incorporated in China, has announced the renewal of its Distribution Framework Agreement and Master Procurement Agreement with Tong Ren Tang Holdings for a term of three years, from January 1, 2026, to December 31, 2028. These agreements, which involve continuing connected transactions, require independent shareholders’ approval due to the applicable percentage ratios exceeding 5%. An extraordinary general meeting will be convened to seek this approval, and an Independent Board Committee has been established to advise shareholders, with an independent financial adviser appointed to assist.
Tong Ren Tang Technologies Co. Ltd. announced that its subsidiary, Beijing Tong Ren Tang Chinese Medicine Company Limited, has received a traditional medicine registration license from Cambodia’s Ministry of Health. This license allows the sale of ‘Tong Ren Tang Angong Niuhuang Wan’ in Cambodia, facilitating the expansion of the company’s distribution channels and market presence in the region. While this development is beneficial for market expansion, it is not expected to have a significant immediate impact on the company’s overall operations or performance.
Tong Ren Tang Technologies Co. Ltd. reported a 7.69% decrease in revenue and a 21.01% decrease in profit attributable to owners for the first half of 2025 compared to the same period in 2024. The company also announced that it will not distribute an interim dividend for this period, reflecting a challenging market environment and potential impacts on stakeholder returns.
Tong Ren Tang Technologies Co. Ltd. announced the interim financial results of its subsidiary, Tong Ren Tang Chinese Medicine, for the first half of 2025. The subsidiary reported a revenue increase to HK$761,736,000, up from HK$664,518,000 in the same period in 2024, with a profit for the period of HK$245,936,000. This financial performance highlights the company’s strong market position and potential growth in the traditional Chinese medicine sector.
Tong Ren Tang Technologies Co. Ltd. announced the results of its extraordinary general meeting held on August 18, 2025, where all proposed resolutions were passed. Key decisions included the appointment of new executive directors, the abolition of the supervisory committee, and the approval of amendments to the company’s procedural rules. These changes are expected to streamline the company’s governance structure and enhance strategic planning, potentially impacting its operational efficiency and market positioning.
Tong Ren Tang Technologies Co. Ltd. has announced the composition of its board of directors and the establishment of four special committees under the board. This organizational structure is likely to enhance the company’s governance and strategic planning, potentially impacting its market positioning and stakeholder relations positively.
Tong Ren Tang Technologies Co. Ltd. has announced amendments to the terms of reference for its Audit Committee, which were adopted by the Board on August 18, 2025. The changes emphasize the importance of having a majority of Independent Non-Executive Directors in the committee, including at least one member with professional qualifications in accounting or financial management. This move is expected to enhance the company’s compliance with the Hong Kong Stock Exchange’s Listing Rules, potentially strengthening its governance and transparency, which could positively impact stakeholders’ trust.
Tong Ren Tang Technologies Co. Ltd. announced the election of Mr. Zhu Dong Sheng as an employee Director, following amendments to the Articles of Association to establish employee Directors. This change, pending approval at the upcoming extraordinary general meeting, reflects a shift in the company’s governance structure, potentially impacting its operational dynamics and stakeholder engagement.
Tong Ren Tang Technologies Co. Ltd. has announced a board meeting scheduled for August 26, 2025, to discuss and approve the unaudited consolidated interim results for the first half of the year. The meeting will also consider the payment of an interim dividend and other potential matters, which could impact the company’s financial performance and shareholder returns.
Tong Ren Tang Technologies Co. Ltd. has announced an extraordinary general meeting scheduled for August 18, 2025, to discuss several key resolutions. These include the appointment of new executive directors, approval of remuneration for certain directors, and significant amendments to the company’s governance structure, such as the abolition of the supervisory committee and the introduction of Employee Directors. These changes are expected to impact the company’s governance and operational strategies.